Intracellular pH Regulates TRAIL-Induced Apoptosis and Necroptosis in Endothelial Cells

Zhu-Xu Zhang,1,2,3,4 Ingrid Gan,1,4 Alexander Pavlosky,1,4 Xuyan Huang,1 Benjamin Fuhrmann,1,5 and Anthony M. Jevnikar1,2,3,5

1Matthew Mailing Centre for Translational Transplantation Studies, London Health Sciences Centre, London, ON, Canada
2Multi-Organ Transplant Program, London Health Sciences Centre, London, ON, Canada
3Division of Nephrology, Department of Medicine, Western University, London, ON, Canada
4Department of Pathology, Western University, London, ON, Canada
5Department of Microbiology & Immunology, Western University, London, ON, Canada

Correspondence should be addressed to Zhu-Xu Zhang; zhuxu.zhang@lhsc.on.ca and Anthony M. Jevnikar; jevnikar@uwo.ca

Received 15 March 2017; Revised 26 May 2017; Accepted 5 July 2017; Published 13 August 2017

Academic Editor: Hai Huang

Copyright © 2017 Zhu-Xu Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

During ischemia or inflammation of organs, intracellular pH can decrease if acid production exceeds buffering capacity. Thus, the microenvironment can expose parenchymal cells to a reduced extracellular pH which can alter pH-dependent intracellular functions. We have previously shown that while silencing caspase-8 in an in vivo ischemia reperfusion injury (IRI) model results in improved organ function and survival, removal of caspase-8 function in a donor organ can paradoxically result in enhanced receptor-interacting protein kinase 1/3- (RIPK1/3-) regulated necroptosis and accelerated graft loss following transplantation. In our current study, TRAIL- (TNF-related apoptosis-inducing ligand-) induced cell death in vitro at neutral pH and caspase-8 inhibition-enhanced RIPK1-dependent necroptotic death were confirmed. In contrast, both caspase-8 inhibition and RIPK1 inhibition attenuated cell death at a cell pH of 6.7. Cell death was attenuated with mixed lineage kinase domain-like (MLKL) silencing, indicating that MLKL membrane rupture, a distinctive feature of necroptosis, occurs regardless of pH. In summary, there is a distinct regulatory control of apoptosis and necroptosis in endothelial cells at different intracellular pH. These results highlight the complexity of modulating cell death and therapeutic strategies that may need to consider different consequences on cell death dependent on the model.

1. Introduction

Inflammatory stress can mediate various forms of cell death, which are relevant to diverse forms of human disease. Cell death is particularly relevant to organ transplantation as stress includes both temporary hypoxia as the organ is retrieved and inflammation associated with reperfusion following reestablishment of blood flow [1, 2]. Apoptosis relies on an intracellular cascade of caspase family members which leads to the formation of membrane-bound apoptotic bodies that are eliminated by noninflammatory phagocytosis such as kidney injury molecule-1- (KIM-1-) mediated cell clearance [3, 4]. Recently, regulated forms of necrosis have been described. Regulated necrosis results in cell lysis and intense inflammation in response to the release of cell contents. The scope of regulated necrosis has evolved rapidly to include not only necroptosis but also ferroptosis, oxytosis, parthanatos, and pyroptosis and others [5].

Necroptosis is dependent on receptor-interacting protein kinase 1/3 (RIPK1/3) to mediate cell death [6, 7]. This pathway is induced by various ligands including TNFα, FasL, and Toll-like receptor (TLR) engagement. Of note, TNF-related apoptosis-inducing ligand- (TRAIL-) mediated apoptosis has long been described as a method to induce cancer cell death through the activation of caspase-8 [8, 9]. More recently, TRAIL has been shown to also induce necroptosis in cancer cells [10–12]. Interestingly, cells can be sensitized to necrototic death through inhibition or alteration of endogenous proteins such as TNF receptor-associated factor 2 (TRAF2) [13] or cellular inhibitor of apoptosis 1/2 (CIAP1/
caspase-8 was not of a benefit by preventing necroptosis. However, silencing of is also demonstrated that elimination of RIPK3 in donor organs [27]. In addition to others, we have shown that silencing in cardiac [26] and renal ischemia reperfusion injury (IRI) increased in clinical organ preservation strategies have provided a benefit of introducing pulsatile perfusion of buffer solutions toer solutions to ameliorate the effects of cold ischemia reperfusion injury. Indeed, the models and the clear lack of benefit in renal IRI and transplantation did not represent identical models [30]. Collectively, these results suggested that TRAIL-induced necrotic cell death can occur without caspase-8 inhibition in low extracellular pH [11], which was a RIPK1, RIPK3, and poly(ADP-ribose) polymerase 1- (PARP-1-) dependent form of cell death [12, 32]. Parenchymal cells are exposed to acidic pH in pathological conditions in the brain, kidney, and heart [33, 34]. pH in organ quickly falls below 7 after ischemia [35–39]. pH changes in cells might thus account for our observations of the somewhat paradoxical benefit of caspase-8 inhibition in acute ischemic models and the clear lack of benefit in a more chronic model, in which acute pH changes have likely resolved. Indeed, the introduction of pulsatile perfusion of buffer solutions to clinical organ preservation strategies have provided a benefit by minimizing intraorgan pH changes and tissue injury [40].

In the present study, we show that inhibition of caspase-8 promotes TRAIL-mediated necroptosis at a normal physiological extracellular and intracellular pH, but not at an acidic pH in murine endothelial cells. Our findings also show that regulated death at an acidic pH relies not only on the function of RIPK1, caspase-8, but also PARP-1, implicating parthanatos [41] as well as apoptosis and necroptosis. These findings provide important new insight into IRI in which caspase-8 inhibition exerts a protective role in a low pH microenvironment, but the same strategy can become proinflammatory as pH normalizes.

2. Materials and Methods

2.1. Microvascular Endothelial Cell (MVEC) Culture. MVECs from mouse hearts were isolated and developed as previously described [31]. MVEC phenotype was confirmed by staining with anti-CD31, anti-CD102, and anti-CD105 (eBioscience) [31]. Cells were grown in complete EGM-2 MV containing 5% FBS, 0.04% hydrocortisone, 0.4% hFGF-b, 0.1% VEGF, 0.1% R3-IFG-1, 0.1% ascorbic acid, 0.1% hEGF, and 0.1% GA-1000 (Lonza).

2.2. pH Conditions. EBM-2 media without growth factors (Lonza) with 50 mM HEPES (Wisten) was adjusted to either pH 7.4 or 6-6.7 using HCl. Cells were grown to monolayers and incubated in this media with the indicated pH. Intracellular pH change was detected using pHrodo red pH indicator (ThermoFisher) and monitored using IncuCyte live-cell imager (Essen Bioscience). High fluorescence intensity is indicative of a lower intracellular pH.

2.3. Western Blot. Protein was isolated from heart tissue using whole cell lysis buffer (20 mM HEPES, 0.4 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM PMSF). Protein concentration was determined using Bio-Rad protein assay (Bio-Rad). Sample buffer (2ME, glycerol, bromophenol blue, and Tris-HCl) was added to the protein and was separated by gel electrophoresis. Protein was transferred to a nitrocellulose membrane using the iBlot dry transfer system (Invitrogen). Membranes were incubated with rabbit anti-MLKL (EPR19697, Abcam), polyclonal rat anti-mouse RIPK1, RIPK3, and poly(ADP-ribose) polymerase 1- (PARP-1-) dependent form of cell death [12, 32]. Parenchymal cells are exposed to acidic pH in pathological conditions in the brain, kidney, and heart [33, 34]. pH in organ quickly falls below 7 after ischemia [35–39]. pH changes in cells might thus account for our observations of the somewhat paradoxical benefit of caspase-8 inhibition in acute ischemic models and the clear lack of benefit in a more chronic model, in which acute pH changes have likely resolved. Indeed, the introduction of pulsatile perfusion of buffer solutions to clinical organ preservation strategies have provided a benefit by minimizing intraorgan pH changes and tissue injury [40].

In the present study, we show that inhibition of caspase-8 promotes TRAIL-mediated necroptosis at a normal physiological extracellular and intracellular pH, but not at an acidic pH in murine endothelial cells. Our findings also show that regulated death at an acidic pH relies not only on the function of RIPK1, caspase-8, but also PARP-1, implicating parthanatos [41] as well as apoptosis and necroptosis. These findings provide important new insight into IRI in which caspase-8 inhibition exerts a protective role in a low pH microenvironment, but the same strategy can become proinflammatory as pH normalizes.
time of treatment, 100 nM of the DNA-intercalating molecule, Sytox green (Invitrogen), was added to detect cell death. Sytox fluorescence (positive cells/well) was measured every hour using IncuCyte live-cell imager (Essen Bioscience).

2.7. Statistical Analysis. Data was compared using Student’s t-test for unpaired values. Data was presented as mean ± standard deviation (SD). p values below 0.05 were considered to be significantly different.

3. Results

3.1. Intracellular pH Was Decreased in MVEC Grown under Acidic Conditions. MVECs were grown to monolayers, and intracellular pH changes in pH 5.4–8.4 medium were detected by pHrodo red fluorescence indicator (Figure 1(a)). Increased fluorescence intensity in cells at acidic pH demonstrated that MVEC intracellular pH was directly related to the pH of the environment (Figures 1(b) and 1(c)). However, intracellular pH restored towards neutral pH following time as indicated by decreased fluorescence intensity in cells (Figure 1(c)). MVEC expressed a high level of TRAIL receptor DR5, but this did not change under acidic conditions (Figure 1(d)).

3.2. Caspase Inhibition Did Not Induce Necroptosis in MVEC under Acidic Conditions. To test if the microenvironment pH could affect the modality of MVEC death, necroptosis was induced by a combination of SMAC mimetic compound (SMC), TRAIL, and caspase-8 inhibitor IETD-fmk. The RIPK1 inhibitor Nec-1s, which blocks necroptosis, was added to cultures at pH 7.4 (Figures 2(a) and 2(d)), pH 6.7 or pH 6.0 (Figures 2(b), 2(c), and 2(d)). At a normal pH of 7.4, TRAIL plus SMC induced a low level of cell death and predictably underwent necroptosis with caspase-8 inhibition using IETD-fmk-enhanced TRAIL-mediated cell death (with IETD 6209 ± 1274 versus without IETD 3701 ± 127 Sytox-positive cells at 12 hours, p = 0.013). TRAIL/IETD-induced
MVEC death could be maximally inhibited by the addition of Nec-1s (1846 ± 808, *p* = 0.002), confirming that this was RIPK-mediated necroptosis. The large reduction of cell death using Nec-1s in TRAIL/SMC cells suggests that the primary form of death is necroptosis, although the residual amount of cell death might be attributed to apoptosis or other forms of cell death. MVEC at pH 6.7 underwent substantial cell death following TRAIL plus SMC treatment alone (untreated 1736 ± 592 versus 9088 ± 1609 Sytox-positive cells at 12 hours, *p* = 0.0005). However, in marked contrast to results at pH 7.4, addition of the caspase-8 inhibitor IETD-fmk did not increase death but substantially blocked cell death (3842 ± 1236 Sytox-positive cells, *p* = 0.004). As well, there was a minimal effect with Nec-1s alone in TRAIL/SMC cells. Cell death at pH 6.0 (Figure 2(c)) is similar to the result at pH 6.7. This data suggests that TRAIL engagement is able to induce cell death at normal and acidic pH environment but that low pH skews cell death to apoptosis. Furthermore, in distinct contrast to pH 7.4, MVEC death can be blocked by caspase-8 inhibition while attempting to attenuate MVEC death at pH 7.4 by caspase-8 inhibition resulted in more MVEC death through necroptosis.

3.3. TRAIL-Induced Cell Death at Acidic Condition Is Dependent on PARP-1. As noted by others [32], necrosis in acid conditions appears to be dependent on PARP-1 activation in cancer cells. To test this in MVEC, cells were treated with the caspase-8-specific inhibitor zIETD-fmk along with the PARP-1 inhibitor 3-ABA and exposed to TRAIL at pH 7.4 (Figures 3(a) and 3(c)) and pH 6.7 (Figures 3(b) and 3(c)). At pH 7.4, MVEC underwent necroptosis following the addition of zIETD-fmk (TRAIL/IETD 10368 ± 2208 versus untreated 1116 ± 136 Sytox-positive cells, *p* = 0.014). The addition of TRAIL/SMC alone increased death minimally by 12 hours, although the PARP-1 inhibitor 3-ABA reduced death below baseline. In contrast, as noted previously at pH 6.7, TRAIL/SMC-induced death could be partially recovered by both zIETD (without IETD 14328 ± 1990 versus with IETD 8581 ± 1100, *p* = 0.012). However, the addition of 3-ABA (1146 ± 672, *p* = 0.0006) reduced cell death to baseline, indicating that PARP-1-dependent cell death as well as apoptosis was occurring under acidic conditions.

3.4. RIPK1 Cleavage under pH 7.4 and 6.7. A previous study has shown that RIPK1 is not cleaved under acidic pH conditions in HT29 cells, which may explain why RIPK1-dependent necrosis can occur at acidic conditions [12]. We next determined if TRAIL treatment under both physiologic and acidic conditions results in RIPK1 cleavage. Interestingly, RIPK1 was cleaved on TRAIL treatment at pH 7.4 as well as pH 6.7 (Figure 4). The cleavage of RIPK1 remained
Figure 3: MVEC death at acidic condition is dependent on PARP-1. (a) MVECs (triplicates) were treated with 100 ng/ml TRAIL, 100 nM SMC, 50 μM zIETD-fmk, and/or 3-ABA at pH 7.4. Kinetic cell death responses were measured by Sytox green staining and quantified by IncuCyte live-cell imager. (b) MVECs were treated with TRAIL, SMC, zIETD-fmk, and/or 3-ABA at pH 6.7. (c) Conclusion of cell death assay at 12 hours. Data shown as mean of triplicates ± SD of fluorescence intensity of Sytox. Similar results were obtained in three repeated experiments. *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 (t-test).
caspase-8 dependent as caspase-8 inhibition by z-IETD-fmk prevented the RIPK1 cleavage under normal and acidic conditions (Figure 4).

3.5. TRAIL-Induced Cell Death at Acidic Condition Is MLKL Dependent. MLKL is the terminal effector molecule for necroptosis as it induces cell membrane rupture after phosphorylation by RIPK3 [20, 42]. To test the contribution of this executioner protein in TRAIL-induced necroptosis under acidic conditions, MLKL was silenced in MVEC using siRNA as confirmed by PCR and Western blot analyses (Figures 5(a) and 5(b)). As shown in Figure 5(c), TRAIL-induced cell death was attenuated in MLKL siRNA-treated cells at pH 6.7 (Sytox-positive cells at 12 hours: 2277 ± 456 versus 7033 ± 753 in scrambled siRNA-treated cells, p = 0.002), confirming that MLKL-dependent necroptosis occurs under acidic conditions.

4. Discussion

Necroptosis contributes to the pathogenesis of many inflammatory diseases. We have previously shown that RIPK3-dependent necroptosis results in increased inflammation and reduced survival in renal and heart transplants. This reduced survival was tightly associated with greater organ injury and release of proinflammatory cell damage-associated molecular patterns (CDAMPs) [30, 31]. We had previously noted that inhibition of caspase-8 yields a benefit during IRI. Caspase-8 silencing in a renal IRI model provided injury protection and improved short-term survival [28, 29]. As organ injury has been shown to improve by targeting apoptosis cell death [28, 29, 43–46], we noted that caspase-8 silencing by siRNA in a kidney allograft model did not have an expected benefit and indeed resulted in massive in vivo necrosis and accelerated graft rejection [30]. These disparate findings using the same intervention in two different models may allude to many differences between acute (IRI) and chronic (transplant) models, clearly diverge in response to selective caspase-8 targeting. Parenchymal cells deprived of oxygen and nutrients in acute IRI and in the early phase of transplant may respond similarly to hypoxia, but IRI resolves quickly while alloimmunity persists in transplantation. These models may highlight the importance of the cellular microenvironment on cell death.

Ischemic cells undergoing anaerobic metabolism generate lactic acid and experience a subsequent drop in intracellular pH. Our study has clearly demonstrated that changes in the pH of the microenvironment of endothelial cells lead to intracellular pH change and altered the function of caspase-8 and other proteins. The mechanism balancing cell death and in particular, apoptosis and necroptosis in endothelial cells changes under acidic conditions. Apoptosis and necroptosis occur simultaneously in response to TRAIL activation in endothelial cell at acidic condition. Our findings provide an important new insight into our observation that caspase-8 inhibition can play a protective role during IRI related to a low intracellular pH and microenvironment, while paradoxically becoming proinflammatory within transplantation in a normal pH environment.

Death in endothelial cells at an acidic pH relies on the function of RIPK1 and caspase-8 (Figures 2 and 3). PARP-1 also appears to be affected by the cellular microenvironment, playing a limited role in necroptosis at pH 7.4 [47, 48], and evident in the low pH cell death observed here (Figure 3) and others [32]. Given the distinct function of caspase-8 and influence of PARP-1, the precise nature of cell death we have observed at low pH which we have termed “acidonecrosis” does not fit well as classical necroptosis or apoptosis. A previous study showed that TRAIL mediates apoptosis through activation of caspase, cytochrome C release, and PARP-1 cleavage in human tumor cells at acidic pH [49, 50]. Other studies have shown that TRAIL can easily induce cell death in tumor cells at pH 6.5 but to a significantly lesser extent at pH 7.4 [11, 12, 32, 49]. In contrast, our study shows that MVEC readily underwent classical necroptosis at pH 7.4 as well as “acidonecrosis” at pH 6–6.7 after TRAIL treatment (Figure 2). Differences in certain death modalities between cell types might allow organ-specific targeted therapies to be more effective.

The mechanism of “acidonecrosis” remains unclear. RIPK1, RIPK3, caspase-8, and PARP-1 all appear to be necessary to induce necrotic death with TRAIL at low pH. Intriguingly, the question whether PARP-1 is activated upstream or downstream of RIPK1 remains uncertain. RIPK1 activation has previously been shown to be the upstream of PARP-1 activation following DNA alkylation [51]. However, inhibition of RIPK1 is also able to inhibit PARP-1 activation and apoptosis-inducing factor (AIF) release from mitochondria following β-lapachone-mediated
regulated necrosis [52]. A unique and novel finding in the present study is the inhibition of TRAIL-mediated cell death following the silencing of MLKL by siRNA in low pH conditions (Figure 5). MLKL activation occurs downstream of RIPK1/RIPK3 phosphorylation and is both necessary and sufficient to induce necroptosis [21, 22, 42, 53]. An important question remains: if MLKL activation is sufficient to induce necroptosis normally, why is PARP-1 activation required for "acidonecrosis"? A recent study may provide some insight in this question, as necroptosis within a transplanted kidney graft can remarkably cause distant lung parthanatos, also by an unknown mechanism [41]. This important observation may suggest that the acidonecrosis we observed in vitro is TRAIL-mediated necroptosis that leads to a paracrine form of parthanatos, also by an unknown mechanism [41]. This important observation may suggest that the acidonecrosis we observed in vitro is TRAIL-mediated necroptosis that leads to a paracrine form of parthanatos, also by an unknown mechanism [41]. This important observation may suggest that the acidonecrosis we observed in vitro is TRAIL-mediated necroptosis that leads to a paracrine form of parthanatos, also by an unknown mechanism [41]. This important observation may suggest that the acidonecrosis we observed in vitro is TRAIL-mediated necroptosis that leads to a paracrine form of parthanatos, also by an unknown mechanism [41]. This important observation may suggest that the acidonecrosis we observed in vitro is TRAIL-mediated necroptosis that leads to a paracrine form of parthanatos, also by an unknown mechanism [41]. This important observation may suggest that the acidonecrosis we observed in vitro is TRAIL-mediated necroptosis that leads to a paracrine form of parthanatos, also by an unknown mechanism [41].

Further studies are required to determine the essential roles of caspase-8, PARP-1 activation, and MLKL during "acidonecrosis." However, it remains controversial whether PARP-1-mediated necrosis parthanatos involves RIPK1/3 and depends on specific cell types used in different studies [32, 47, 51]. Our data suggested that PARP-1 participates in "acidonecrosis" (Figure 3) in MVEC. It is possible that PARP-1 may be the downstream effect of both apoptosis and necrosis at acidic pH [32, 54].

Under conditions of acidic intracellular pH, cellular functions such as ion transport, enzyme activities, protein synthesis, and DNA synthesis can be diminished or altered [33, 34, 55, 56]. Acidic pH conditions may result in a decreased intracellular level of K⁺ because of H⁺/K⁺ pump activity. A decrease of K⁺ concentration results in the activation of caspases and nucleases and thus leads to DNA damage [57, 58] and apoptosis [59–61]. This mechanism might explain why acidosis induces apoptotic cell death in various types of cells, including endothelial cells by activating caspases [50, 62–64]. However, other studies showed that...
acidosis protects endothelial cells from apoptosis by blocking caspase activation or enhancing expression of antiapoptotic molecules [65–68]. It requires further study to define different types of cell death program in different cell types.

A recent study has shown that acidosis-induced necroptosis in neurons is dependent on acid-sensing ion channel 1a (ASIC1a)–mediated RIPK1 phosphorylation [69]. Acid-sensing ASIC1a mediation of RIPK activation may thus explain how RIPKs are activated even in the presence of caspase-8 during acidosis. A previous study also showed that RIPK1 is cleaved at normal pH but not cleaved at acidic pH in tumor cells [12]. While these results might explain why RIPK1 can induce necroptosis despite in the presence of caspase-8 activity [11, 12], our data showed that RIPK1 is partially cleaved at normal and acidic pH conditions (Figure 4). This indicates caspase-8-mediated RIPK1 cleavage at pH 7.4 is not altered when pH drops to acidic condition. It is likely that TRAIL induces apoptosis and necroptosis simultaneously at acidic pH in MVEC, as RIPK1 is only partially cleaved (Figure 4) and the inhibition of either caspase-8 or RIPK1 could attenuate acidonecrosis (Figures 2 and 3).

5. Conclusions

This study highlights the importance of the cellular microenvironment on the magnitude, progression, and outcome of several forms of programmed cell death. For cancer therapeutics, the cell type and surrounding tumor microenvironment appear to play important roles in increasing the sensitivity of cells to different modalities of cell death, which is of central importance in maximizing cancer cell death. In contrast, with the goal in transplantation being the opposite with maximum reduction of cell death, the nature and timing of antideath strategies during organ procurement and transplantation becomes complex as we test normothermic and hypothermic perfusion strategies as well as different perfusion solutions with altered buffering capacity to minimize ischemic injury. The extracellular microenvironment including pH clearly regulates the intracellular and subsequently the cell death programs that result in inflammation. Blocking multiple pathways of cell death including apoptosis and necroptosis and others perhaps may be more effective in preventing IRI-induced cell death and organ injury during transplantation than targeting a single-cell death pathway.

Conflicts of Interest

There are no financial disclosures or conflicts of interest in this study.

Acknowledgments

This study was supported by the research funding from the Canadian Institutes of Health Research (CIHR, AM), ZXZ, MOP-115048, and MOP-111180). This work is part of the Canadian National Transplant Research Program (CNTRP) and was supported by the CIHR and partners (TFU-127880).

References


S. Krick, O. Platoshyn, M. Sweeney, H. Kim, and J. X. Yuan,
S. P. Yu, C. H. Yeh, S. L. Sensi et al.,
E. D. Burg, C. V. Remillard, and J. X. Yuan,
R. M. Graham, D. P. Frazier, J. W. Thompson et al.,

J. Sosna, S. Philipp, J. Fuchslocher Chico et al.,
Y. J. Lee, J. J. Song, J. H. Kim, H. R. Kim, and Y. K. Song,
R. M. Graham, D. P. Frazier, J. W. Thompson et al.,
S. Kumar, S. Kasseckert, S. Kostin et al.,
J. Sosna, S. Philipp, J. Fuchslocher Chico et al.,
H. J. Park, J. C. Lyons, T. Ohtsubo, and C. W. Song,
Y. J. Lee, J. J. Song, J. H. Kim, H. R. Kim, and Y. K. Song,
Y. Xu, S. Huang, Z. G. Liu, and J. Han,
D. M. Moujalled, W. D. Cook, J. M. Murphy, and D. L. Vaux,
V. Nikoletopoulou, M. Markaki, K. Palikaras, and N.
F. M. Hughes Jr., C. D. Bortner, G. D. Purdy, and J. A.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama and J. C. Reed,
J. E. Park, K. J. Min, T. I. Lee, Y. H. Yoo, Y. S. Kim, and T. K.
J. Sosna, S. Philipp, J. Fuchslocher Chico et al.,
Y. J. Lee, J. J. Song, J. H. Kim, H. R. Kim, and Y. K. Song,
Y. Xu, S. Huang, Z. G. Liu, and J. Han,
D. M. Moujalled, W. D. Cook, J. M. Murphy, and D. L. Vaux,
V. Nikoletopoulou, M. Markaki, K. Palikaras, and N.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.
S. Matsuyama, J. Llopis, Q. L. Deveraux, R. Y. Tsien, and J. C.
K. Cain, C. Langlais, X. M. Sun, D. G. Brown, and G. M.